Can Sarica, Christopher R Conner, Kazuaki Yamamoto, Andrew Yang, Jürgen Germann, Melissa M Lannon, Nardin Samuel, Michael Colditz, Brendan Santyr, Clement T Chow, Christian Iorio-Morin, David H Aguirre-Padilla, Stefan Thomas Lang, Artur Vetkas, Cletus Cheyuo, Aaron Loh, Ghazaleh Darmani, Oliver Flouty, Vanessa Milano, Michelle Paff, Mojgan Hodaie, Suneil K Kalia, Renato P Munhoz, Alfonso Fasano, Andres M Lozano
BACKGROUND: Deep brain stimulation (DBS) is an approved treatment option for Parkinson's Disease (PD), essential tremor (ET), dystonia, obsessive-compulsive disorder and epilepsy in the United States. There are disparities in access to DBS, and clear understanding of the contextual factors driving them is important. Previous studies aimed at understanding these factors have been limited by single indications or small cohort sizes. The aim of this study is to provide an updated and comprehensive analysis of DBS utilization for multiple indications to better understand the factors driving disparities in access...
October 2023: Lancet Reg Health Am